Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus gemcitabine vs placebo plus gemcitabine in KRAS wild-type advanced pancreatic cancer
CTR20131232Phase 3Completed
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in pancreatic adenocarcinoma (PDAC), sponsored by Biotech Pharmaceutical Co., Ltd.. Started May 2015; status: completed.
02
Drugs
nimotuzumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20131232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131232.